Uncategorized

FDA adcomm shoots down Capricor’s Duchenne cell therapy after meeting marked by statistical dispute

Published

on

A panel of experts today voted against Capricor’s cell therapy for Duchenne muscular dystrophy, capping off an advisory committee meeting marked by statistical confusion.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version